ライフサイエンスコーパス: pralatrexate

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 115 patients enrolled, 111 were treated with pralatrexate.

2 alized papular rash, he received one dose of pralatrexate.

3 Patients were treated with pralatrexate (10 to 25 mg/m(2)) and romidepsin (12 to 14

4 Pralatrexate 15 mg/m(2)/wk for 3/4 weeks shows high acti

5 The recommended phase 2 dose was defined as pralatrexate 25 mg/m(2) and romidepsin 12 mg/m(2) every

6 y evaluated the efficacy and tolerability of pralatrexate, a novel antifolate with promising activity

7 Coadministration of pralatrexate and romidepsin was safe, well tolerated, wi

8 linic, such as pemetrexed, methotrexate, and pralatrexate, are transported into tumor cells primarily

9 ell lymphomas and TCL have demonstrated that pralatrexate demonstrates activity superior to tradition

10 e-escalation strategy identified recommended pralatrexate dosing for patients with CTCL that demonstr

11 The high affinity of pralatrexate for RFC-1 significantly improves its intern

12 and clinical studies have demonstrated that pralatrexate has significant activity against TCL.

13 Pralatrexate has significant single-agent activity in pa

14 We investigated the effects of pralatrexate in a patient with adult T-cell lymphoma/leu

15 To our knowledge, PROPEL (Pralatrexate in Patients with Relapsed or Refractory Per

16 Pralatrexate induced durable responses in relapsed or re

17 Here we present in vivo evidence that pralatrexate-induced erosions in skin affected by adult

18 Pralatrexate-induced skin erosions may indicate response

19 Pralatrexate is a novel antifolate designed to have high

20 Pralatrexate is a novel antifolate with high affinity fo

21 Pralatrexate is a novel antifolate, which shows increase

22 Pralatrexate is an antifolate designed to be internalize

23 is and are not the result of cytotoxicity by pralatrexate on keratinocytes.

24 single institution dose-escalation study of pralatrexate plus romidepsin designed to determine the d

25 els of PTCL, we initiated a phase 1 study of pralatrexate plus romidepsin in patients with relapsed/r

26 The phase 1 study of pralatrexate plus romidepsin resulted in a high response

27 en, obatoclax, and gossypol), antifols (e.g. pralatrexate), proteasome inhibitors (e.g. bortezomib),

28 ion, have been investigated in this context: pralatrexate, romidepsin, belinostat, and brentuximab ve

29 US Food and Drug Administration approval of pralatrexate, the first drug approved for this disease.

30 influence the clinical decision to continue pralatrexate treatment.

31 Pralatrexate was administered for a median of 4 cycles;

32 Romidepsin and pralatrexate were approved by the US Food and Drug Admin

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。